Tuesday, 20 Mar 2018

You are here

CARES Study- More CV Deaths with Febuxostat

The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat. (Citation source bit.ly/2HtUEaz)

The study (also reported in the New England Journal of Medicine) included 6190 gout patients (with a history of CV disease) who received febuxostat or allopurinol, and followed for a median of 32 months. The primary endpoint was a combination of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina with urgent revascularization.

The primary end-point event occurred in 335 patients (10.8%) in the febuxostat group and in 321 patients (10.4%) in the allopurinol group (hazard ratio 1.03); the rate of gout flares was similar between groups. 

But all-cause and cardiovascular mortality was higher in the febuxostat group than in the allopurinol group (hazard ratio for death from any cause, 1.22 [95% CI, 1.01 to 1.47]; hazard ratio for cardiovascular death, 1.34 [95% CI, 1.03 to 1.73]). The risk of death from cardiovascular disease was 34 percent higher with febuxostat and all cause deaths were 22 percent higher with febuxostat. 

Febuxostat was approved in 2009. At the time, the FDA reviewed old and supplemental evidence regarding the risk of cardiovascular problems.

The trial is hampered by high rate of regimen discontinuations (57%) and those who discontinued follow-up (45%).

Thus in CV high risk gout patients febuxostat did not fare as well as allopurinol.

Add new comment

More Like This

Does Dose Escalation Help in Gout?

Contrary to expectations, dose escalation of allopurinol among patients with gout did not improve survival, a 10-year observational study found.

Gout Crystal Deposition is Deeper than its Measures

Dalbeth and colleagues have published that among gout patients without palpable tophic and despite long term allopurinol, nearly half have monosodium urate (MSU) as detected by Dual-energy CT (DECT).  The total body urate deposition is even greater in those with higher sUA and evidence of severe disease. 

Probenecid Benefits Heart Failure

In animal studies, probenecid was shown to have positive inotropic effects on the cardiomyocyte mediated by transient receptor potential vanilloid 2 activation. This concept was further studied in 20 patients with heart failure with reduced ejection fraction where probenecid was shown to improve cardiac function after just one week of probenecid treatment.

T2T Improves Primary Care Gout Management

Researchers from Geisinger Medical center tested a pilot primary care gout management improvement intervention, and demonstrated significantly improved primary care gout management metrics when a treat to target approach was implemented. 

New BSR 2017 Gout Guidelines (Best of 2017)

The British Society for Rheumatology/British Health Professionals in Rheumatology first published a guideline for the management of gout in 2007. They have just updated and published their new guideline, largely because of new therapies, an increasing incidence of gout, low penetrance of urate lowering therapies, and the inability to achieve a target serum uric acid level.